Diabetes Mellitus, Type 2
"Diabetes Mellitus, Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Descriptor ID |
D003924
|
| MeSH Number(s) |
C18.452.394.750.149 C19.246.300
|
| Concept/Terms |
Diabetes Mellitus, Type 2- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Noninsulin-Dependent
- Diabetes Mellitus, Ketosis-Resistant
- Diabetes Mellitus, Ketosis Resistant
- Ketosis-Resistant Diabetes Mellitus
- Diabetes Mellitus, Non Insulin Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Non-Insulin-Dependent Diabetes Mellitus
- Diabetes Mellitus, Stable
- Stable Diabetes Mellitus
- Diabetes Mellitus, Type II
- NIDDM
- Diabetes Mellitus, Noninsulin Dependent
- Diabetes Mellitus, Maturity-Onset
- Diabetes Mellitus, Maturity Onset
- Maturity-Onset Diabetes Mellitus
- Maturity Onset Diabetes Mellitus
- MODY
- Diabetes Mellitus, Slow-Onset
- Diabetes Mellitus, Slow Onset
- Slow-Onset Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Noninsulin-Dependent Diabetes Mellitus
- Noninsulin Dependent Diabetes Mellitus
- Maturity-Onset Diabetes
- Diabetes, Maturity-Onset
- Maturity Onset Diabetes
- Type 2 Diabetes
- Diabetes, Type 2
- Diabetes Mellitus, Adult-Onset
- Adult-Onset Diabetes Mellitus
- Diabetes Mellitus, Adult Onset
|
Below are MeSH descriptors whose meaning is more general than "Diabetes Mellitus, Type 2".
Below are MeSH descriptors whose meaning is more specific than "Diabetes Mellitus, Type 2".
This graph shows the total number of publications written about "Diabetes Mellitus, Type 2" by people in this website by year, and whether "Diabetes Mellitus, Type 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 0 | 3 |
| 1997 | 3 | 0 | 3 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 4 | 0 | 4 |
| 2001 | 3 | 0 | 3 |
| 2002 | 2 | 0 | 2 |
| 2003 | 7 | 1 | 8 |
| 2004 | 5 | 1 | 6 |
| 2005 | 9 | 1 | 10 |
| 2006 | 7 | 0 | 7 |
| 2007 | 4 | 3 | 7 |
| 2008 | 8 | 2 | 10 |
| 2009 | 8 | 1 | 9 |
| 2010 | 9 | 1 | 10 |
| 2011 | 7 | 0 | 7 |
| 2012 | 7 | 1 | 8 |
| 2013 | 4 | 2 | 6 |
| 2014 | 13 | 2 | 15 |
| 2015 | 7 | 1 | 8 |
| 2016 | 8 | 4 | 12 |
| 2017 | 7 | 2 | 9 |
| 2018 | 14 | 0 | 14 |
| 2019 | 15 | 0 | 15 |
| 2020 | 8 | 1 | 9 |
| 2021 | 13 | 1 | 14 |
| 2022 | 5 | 0 | 5 |
| 2023 | 8 | 0 | 8 |
| 2024 | 3 | 2 | 5 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diabetes Mellitus, Type 2" by people in Profiles.
-
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025 Sep 18; 393(11):1065-1076.
-
Use of finerenone in patients with chronic kidney disease at high risk of heart failure. Metabolism. 2025 Aug; 169:156297.
-
Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial. BMJ. 2024 10 15; 387:e080122.
-
Glycaemic treatment of newly diagnosed type 2 diabetes. Diabetes Obes Metab. 2024 Nov; 26(11):5492-5493.
-
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone. BMJ Open. 2024 07 16; 14(7):e081121.
-
Real-world evidence for computerized insulin dose-adjustment algorithms in the effective use of continuous glucose monitoring by primary care clinicians. Diabetes Obes Metab. 2024 Aug; 26(8):3475-3477.
-
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism. 2024 Oct; 159:155931.
-
Systemic and ocular outcomes in patients with young-onset type 2 diabetes. J Diabetes Complications. 2024 02; 38(2):108670.
-
Cardio-renal-metabolic disease in primary care setting. Diabetes Metab Res Rev. 2024 Mar; 40(3):e3755.
-
In adults with BMI =27 kg/m2 and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk. Ann Intern Med. 2023 11; 176(11):JC129.